A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder

Trial Profile

A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Trigriluzole (Primary)
  • Indications Obsessive-compulsive disorders
  • Focus Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 2 Nov 2019 to 31 Dec 2019.
    • 21 Nov 2017 Planned primary completion date changed from 3 Nov 2018 to 31 Dec 2018.
    • 21 Nov 2017 Planned initiation date changed from 12 Nov 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top